Core Viewpoint - The stock of CSPC Pharmaceutical Group (1093.HK) experienced a significant decline of 12.54%, closing at HKD 9.35, with trading volume exceeding HKD 3.8 billion following the announcement of a strategic research and development collaboration with AstraZeneca [1] Group 1: Company Developments - CSPC Pharmaceutical Group has signed a strategic research and development collaboration and licensing agreement with AstraZeneca to utilize its proprietary sustained-release drug delivery technology platform and AI discovery platform for innovative long-acting peptide drugs [1] - The agreement entails comprehensive strategic cooperation between CSPC and AstraZeneca in the discovery of innovative peptide molecules and the development of long-acting delivery products [1] - CSPC will continue to advance its existing preclinical long-acting peptide pipeline while also discovering and developing other innovative long-acting peptide products for AstraZeneca [1]
港股异动丨石药集团放量大跌超12%